A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.The verdict in an unusual patent infringement case marked a defeat for the government and activists who have pushed it to more aggressively assert its financial and legal rights to medicines developed with the help of public funding. The Trump administration brought the lawsuit in 2019 in part because of concern over the high price Gilead was charging.The legal dispute centered on who devised the idea of using a Gilead medication for people at high risk of contracting H.I.V., or the human immunodeficiency virus, which causes AIDS. The two versions of the drug — Truvada and the newer Descovy — have generated huge profits for Gil …
Browse
Business Central
Accelerate growth with 1BusinessWorld's Global Business Profile
Sign up for free or use coupon code 1BW50 for 50% discount on your subscription
Sign up nowLatest Business News
- Global Tourism Reimagined: Building Bridges for a Brighter Future (12/1/2024) - Building Bridges in the New Era: Annette Cardenas Advances Global… Read more...
- Leadership at Sea: The Art of Curating Unforgettable Journeys (11/24/2024) - Lisa Bauer Redefines Excellence Through a People-Driven Vision for Cruise… Read more...
- The Critical Role of Psychological Safety in Business Success (11/21/2024) - How Creating Cultures of Rewarded Vulnerability Unlocks Innovation, Engagement, and… Read more...
- Empowering Growth: The Leadership Imperative for Building Entrepreneurial Ecosystems (11/20/2024) - In today's rapidly evolving business landscape, characterized by technological advancements… Read more...
- Maximizing Retail Success: How Specialized Technology Transforms Customer Experience (11/14/2024) - Harnessing Domain-Specific Solutions for Enhanced Personalization and Efficiency The retail… Read more...
- Precision Health and the Future of Wearable Technology (11/10/2024) - Leon Eisen on Precision Health: A Roadmap for Investors in… Read more...